Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and p... Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine. 詳細を表示
SOUTH SAN FRANCISCO, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver...
Received Rare Pediatric Disease Designation from U.S. Food and Drug Administration for TN-201 for MYBPC3-associated Hypertrophic Cardiomyopathy Received UK Clearance to Initiate Clinical Testing...
期間 † | 前日比 | 前日比 % | 始値 | 高値 | 安値 | 平均出来高 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.135 | -6.3679245283 | 2.12 | 2.23 | 1.9 | 331684 | 2.04238541 | CS |
4 | -0.795 | -28.5971223022 | 2.78 | 2.85 | 1.88 | 405482 | 2.15297675 | CS |
12 | -0.915 | -31.5517241379 | 2.9 | 4.06 | 1.88 | 357668 | 2.74545188 | CS |
26 | -2.905 | -59.4069529652 | 4.89 | 5.32 | 1.88 | 353827 | 3.38350944 | CS |
52 | -0.945 | -32.252559727 | 2.93 | 7.01 | 1.66 | 423328 | 3.68604304 | CS |
156 | -16.745 | -89.4020288308 | 18.73 | 32 | 1.64 | 324586 | 5.06209263 | CS |
260 | -17.515 | -89.8205128205 | 19.5 | 32 | 1.64 | 323557 | 5.7998539 | CS |
顧客サポート: +44 (0) 203 8794 460 | support@advfn.com
ADVFNのサービスをご利用いただくには、利用規約